UBS Raises price Target on Foundation Medicine (FMI) to $22
- Wall Street opens higher as financial stocks rise
- Oil falls on firmer dollar and profit-taking after OPEC rally
- Costco Wholesale (COST) Tops Q4 EPS by 4c; Comps Rose 3%
- Deutsche Bank woes keep stocks on steep slide
- Pre-Open Stock Movers 09/30: (LXK) (AUPH) (DB) Higher; (OPHT) (CAMP) (CTSH) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
UBS reiterated a Neutral rating on Foundation Medicine (NASDAQ: FMI), and raised the price target to $22.00 (from $16.00), following the company's announced expanded Local Coverage Determination.
Analyst Jonathan Groberg commented, "Palmetto, a Medicare contractor, announced last Thursday an expanded Local Coverage Determination (LCD) to include all stage IIIB/IV non-small cell lung cancer (NSCLC) patients. This new policy now provides coverage for comprehensive genomic profiling (CGP) for metastatic NSCLC patients who have not been tested for genomic mutations or who have tested negative for EGFR mutations. This is important for patients as CGP detected alterations may indicate eligibility for targeted treatment or immunotherapy."
Shares of Foundation Medicine closed at $23.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Cuts Price Target on Tractor Supply (TSCO) Following Petsense Acquisition
- CVS Health (CVS): Cutting Estimates On Pricing Concerns - Leerink
- Veeva Systems (VEEV): Analyst Day Notes, Raising PT - Needham
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!